Glaxosmithkline Share News (GSK)

Thursday newspaper round-up: BoE, China, North Sea

The Serious Fraud Office has opened a criminal investigation into the Bank of England over the potential rigging of money market auctions. Confirmation of the inquiry came last night with the central bank already under scrutiny over an earlier investigation into the foreign exchange-rigging scandal.

Bristol's $1 bln Bavarian deal may signal cancer vaccine revival

By Ben Hirschler LONDON, March 4 (Reuters) - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic . The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's ther

ANALYST VIEW-Genmab 2014 operating profit above guidance

March 3 (Reuters) - Danish biotech firm Genmab reported 2014 operating income (EBIT) above its own guidance late on Monday. Genmab's operating profit rose to 265 million Danish crowns ($40 million), up from 69 million crowns in 2013. It had previously predicted profits would come in at bet

UK MIDDAY BRIEFING: Tullow Oil Takes New Hit, Set To Drop From FTSE 100

TOP NEWS: UK Manufacturing Activity Hits Seven Month High In February

UPDATE 1-GSK and Novartis complete deals to reshape both drugmakers

(Adds details on drugs, background) By Ben Hirschler LONDON, March 2 (Reuters) - GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture w

UK MORNING BRIEFING: Intertek Leads Firm Early Market

GSK completes Novartis asset-swap deal, plans to return $4bn to shareholders

Pharmaceutical giant Glaxosmithkline (GSK) has finally completed its multibillion-dollar three-part asset-swap deal with Swiss peer Novartis, clearing the way for a big cash return for shareholders. The transaction, first announced in April 2014, saw GSK buy the bulk of Novartis' global vaccines bus

GlaxoSmithKline To Set Out Guidance When It Reports On May 6

GSK and Novartis complete deals to reshape both drugmakers

LONDON, March 2 (Reuters) - GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's v

China says to implement drug distribution reforms

BEIJING, Feb 28 (Reuters) - China said on Saturday it would implement drug distribution reforms including centralisation measures designed to cut prices and reduce corruption. The State Council, China's cabinet, said it urged drug manufacturers to negotiate directly with hospitals on paymen

UPDATE 1-Decision on Ebola mass vaccination in August at earliest - WHO

* Will depend on results of trials, epidemic's course * Guinea, Liberia, Sierra Leone to conduct phase III trials * WHO says know vaccines safe (adds details, background) By Stephanie Nebehay GENEVA, Feb 27 (Reuters) - An independent advisory body will decide in August a

Decision on widespread Ebola vaccination in August at earliest - WHO

GENEVA, Feb 27 (Reuters) - An independent advisory body will decide in August at the earliest on whether to recommend widespread introduction of Ebola vaccine, depending on results of clinical trials and the epidemic's course, the World Health Organization said on Friday. Reporting on a thr

UPDATE 2-GSK's new chairman Hampton to take charge in May

* RBS chairman Hampton takes reins at GSK on May 7 * Move follows appointment of Davies to lead RBS * GSK facing tough times; CEO's 2014 bonus cut by 51 pct (Adds detail on CEO's reduced bonus, paragraph 5) By Ben Hirschler LONDON, Feb 26 (Reuters) - GlaxoSmithKline said

GSK's new chairman Hampton to take charge in May

LONDON, Feb 26 (Reuters) - GlaxoSmithKline said on Thursday that its chairman-designate Philip Hampton would take charge of Britain's biggest drugmaker from May 7, marking an earlier transition than initially anticipated. Hampton, who chairs Royal Bank of Scotland, was named as the pharmace